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Abstract*
Electronic nose (e-nose) devices may be used to identify volatile organic com-
pounds (VOCs) in exhaled breath. VOCs generated via metabolic processes
are candidate biomarkers of (patho)physiological pathways. We explored the
feasibility of using an e-nose to generate human “breathprints” at high alti-
tude. Furthermore, we explored the hypothesis that pathophysiological pro-
cesses involved in the development of acute mountain sickness (AMS) would
manifest as altered VOC profiles. Breath analysis was performed on Sherpa
and lowlander trekkers at high altitude (3500 m). The Lake Louise Scoring
(LLS) system was used to diagnose AMS. Raw data were reduced by principal
component (PC) analysis (PCA). Cross validated linear discriminant analysis
(CV-LDA) and receiver-operating characteristic area under curve (ROC-AUC)
assessed discriminative function. Breathprints suitable for analysis were
obtained from 58% (37/64) of samples. PCA showed significant differences
between breathprints from participants with, and without, AMS; CV-LDA
showed correct classification of 83.8%, ROC-AUC 0.86; PC 1 correlated with
AMS severity. There were significant differences between breathprints of par-
ticipants who remained AMS negative and those whom later developed AMS
(CV-LDA 68.8%, ROC-AUC 0.76). PCA demonstrated discrimination between
Sherpas and lowlanders (CV-LDA 89.2%, ROC-AUC 0.936). This study
demonstrated the feasibility of breath analysis for VOCs using an e-nose at
high altitude. Furthermore, it provided proof-of-concept data supporting e-
nose utility as an objective tool in the prediction and diagnosis of AMS. E-
nose technology may have substantial utility both in altitude medicine and
under other circumstances where (mal)adaptation to hypoxia may be impor-
tant (e.g., critically ill patients).
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Introduction
The physiological responses to hypoxemia are diverse and
the mechanisms that underpin human hypoxic adaptation
remain unclear (Grocott and Montgomery 2008). Within
critical care, there is substantial interindividual variation
in patients’ response to hypoxemia and there is difficulty
identifying those who will respond adversely (Grocott
et al. 2007). Similarly, there is considerable variation in
performance when individuals are exposed to hypobaric
hypoxia at high altitude, and there is no reliable method
to identify those at risk of developing acute mountain
sickness (AMS) (Martin et al. 2010). These parallels have
prompted research into healthy subjects at high altitude
to provide novel insights into the (patho)physiology of
hypoxic (mal)adaptation in critically ill patients (Grocott
et al. 2007). Of particular interest are the Sherpa people
who demonstrate extraordinary adaptation to high alti-
tude yet show no conventional markers of improved sys-
temic oxygen delivery (Gilbert-Kawai et al. 2014). A
better understanding of Sherpa physiology could provide
candidates for improved management strategies in our
sickest hypoxemic patients (Martin et al. 2013).
Volatile organic compounds (VOCs) are a diverse
group of carbon-based molecules, generated via various
metabolic processes. Endogenous VOCs have a multi-sys-
temic origin and are transported within the blood before
being excreted in exhaled breath. The number of VOCs
in exhaled breath exceeds several thousand and the profile
varies according to underlying inflammatory states(Bus-
zewski et al. 2007; van de Kant et al., 2012). As such
these compounds pose enormous potential as pathophysi-
ological biomarkers. The Cyranose 320 (Sensigent, USA)
is a handheld vapor analyser, known as an electronic nose
(e-nose). Although not designed for clinical use, it can be
used to analyze exhaled VOCs. The 32 carbon polymer
sensors absorb volatiles causing a change in the sensors’
electrical resistance. The magnitude and distribution of
changes of resistance creates a specific pattern or “breath-
print” for that sample. Analysis by pattern recognition
algorithms can then discriminate between samples, with-
out identifying individual molecular components. E-noses
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have been shown to be capable of distinguishing between
various respiratory diseases, including lung cancer and
asthma (Machado et al. 2005; Dragonieri et al., 2007,
2009; Fens et al. 2009).
In this study, we hypothesized that the pathophysiology
involved in the development of AMS would manifest as
altered VOC profiles in exhaled breath. Furthermore, we
hypothesized that those groups known to show superior
adaptation to hypoxemia, namely Sherpa people, will
express this physiological advantage in their breathprints.
Specifically, breath analysis using an e-nose could be used
to identify individuals suffering from AMS and to distin-
guish resistant or susceptible individuals.
Study objective
To develop a method for breath analysis, using an e-nose
(Cyranose 320) that is feasible to use in an austere high
altitude environment. Secondary aims were to investigate
if breath analysis during early exposure to high altitude
hypobaric hypoxia can be used to: (1) diagnose those suf-
fering from AMS; (2) identify those at risk of developing
AMS; and (3) to distinguish Sherpas from lowlanders.
Methods
Ethical approval
Ethical approval was obtained from the Nepal Health
Research Council (reference 139/2012) and the University
College London Research Ethics Committee (reference
3750/006). Written informed consent was obtained from
all participants and the study complied with the standards
set by the Declaration of Helsinki.
Participants
Participants were adult volunteer trekkers (aged over
18 years) recruited from two distinct population groups:
lowland residents (primarily European with no Tibetan/
Andean/Ethiopian ancestry, residing below 1300 m alti-
tude) and indigenous Sherpas with confirmed Tibetan
ancestry. Study eligibility was dependent upon good
health (determined through physician review of a detailed
health questionnaire).
Study design
This study formed part of a research programme that
made up the “Xtreme Everest 2” expedition to Nepal
(2013) (Gilbert-Kawai et al. 2015). Xtreme Everest 2 had
a prospective observational design that has been detailed
previously (Gilbert-Kawai et al. 2015). The aim of the
expedition was to investigate the physiological mecha-
nisms involved in acclimatization and adaptation to
hypobaric hypoxia. Participants were assigned into trek-
king groups which followed identical ascent profiles. Par-
ticipants provided a single breath sample on reaching
high altitude at Namche Bazaar (3500 m), before contin-
uing on to Everest Base Camp (5300 m). Participants
completed a daily diary describing any AMS symptoms at
baseline and for the duration of the trek. The criterion
for AMS diagnosis was a Lake Louise Score (LLS) of 3 or
more, including the presence of a headache (Roach et al.
1993).
Exhaled breath analysis
A validated method for breath sample collection (Drago-
nieri et al. 2007) was modified to adapt to the logistical
and environmental restrictions of the expedition. A major
objective was to reduce exogenous contaminants. All sub-
jects avoided eating/drinking, smoking, brushing teeth or
using inhaler devices for 2 h prior to breath sampling. To
minimize contamination by ambient VOCs, subjects
underwent 5 min tidal breathing of VOC-filtered air. This
was achieved using a VOC filter (A2 vapor filter, North
Safety Products Europe), to which an angle piece (elbow
connector 15M-22M/15F, Intersurgical, UK) was attached
to allow subjects to inhale through the filter apparatus
and exhale into ambient air. Nose clips were worn to pre-
vent nasal entrainment of nonfiltered ambient air. An
expiratory vital capacity breath was then collected into an
inert Nalophan bag. This collection system was made by
cutting 60 cm sections of double-layered Nalophan sheet:
one end was sealed using a plastic locking system (Clip-n-
Seal, USA); the other end was sealed around a 20 cm sec-
tion of polytetrafluoroethylene tubing using a cable tie.
The polytetrafluoroethylene tube then served as a mouth-
piece to allow subjects to provide their sample. After col-
lection, the bag was immediately connected to the sample
inlet of the e-nose via the polytetrafluoroethylene tubing.
VOC filtered air was used as reference air for the 60 sec
baseline draw, followed by a 40-sec sample draw and
completed by 180 sec of purging with VOC filtered air
(60 sec via the purge inlet and 120 sec via the sample
inlet). The image in Figure 1 shows the e-nose and appa-
ratus set-up.
Data analysis
Offline analysis of raw e-nose data was performed, using
SPSS software (version 20.0). After verifying normal dis-
tribution, data were reduced by principal component
analysis (PCA). PCA is a statistical procedure for reducing
high-dimensional datasets into smaller sets of linearly
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uncorrelated variables, called principal components, that
retain the trends and patterns of the original data (Lever
et al. 2017). After PCA, principal components with eigen-
values greater than 1 were retained for further analysis,
which is in agreement with the Kaiser Criterion (Yeomans
and Golder 1982). A bootstrapped-independent samples
t-test was then used to assess if the preserved principal
components were discriminative between groups. Based
on the differentiating principal components, cross-vali-
dated linear discriminant analysis (CV-LDA) was per-
formed and receiver operating characteristic (ROC) area
under curve (ROC-AUC, 95% CI) was calculated to
classify cases into categorical divisions. ANOVA and
regression analysis were used to ascertain correlation
between principal components and LLS for AMS.
Results
Sixty-four breath samples were obtained, from which 37 sam-
ples were suitable for analysis. Four samples were excluded
from the first day of testing due to failed sample draws;
changing the pump setting to high-speed prevented this
recurring. The remaining 23 exclusions were deemed anoma-
lies and are discussed further under “study limitations”.
Demographics and baseline characteristics
The 37 subjects were divided into 18 Sherpas and 19 low-
landers (median age 24.5 and 31.0 years, respectively),
with similar male: female ratios. Four Sherpas and one
lowlander were smokers. Two participants suffered from
mild, well-controlled asthma; there were no other respira-
tory diseases amongst the trekkers. There was a signifi-
cantly greater proportion of lowlanders (72%) diagnosed
with AMS (P < 0.001). It was not possible to exclude
AMS for one lowlander at Everest Base Camp because of
missing diary data.
Diagnostic ability of breath analysis with an
e-nose
Four of 37 participants (all lowlanders) suffered from
AMS at Namche Bazaar. From the original 37 breath-
prints produced by the e-nose, three principal compo-
nents with an eigenvalue larger than 1 were derived,
capturing 83% of the variance within the total dataset.
The subsequent bootstrapped independent samples t-test
between AMS positive and AMS negative participants
resulted in significant outcomes for both principal com-
ponent 1 and principal component 2 (P = 0.006 and
P = 0.001, respectively) (Fig. 2). CV-LDA showed correct
classification of 83.8% of all cases and an ROC-AUC of
0.86  0.12 (Fig. 3). Sensitivity (0%) and specificity









Figure 1. Photograph of e-nose (Cyranose 320) and breath
analysis apparatus.
Figure 2. Boxplots comparing principal components 1 and 2 of
AMS negative and AMS positive breathprints at Namche Bazaar.
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(94%) indicated that the model is unstable with the skew
distribution of 33 AMS negative and 4 AMS positive par-
ticipants. A plot of the two discriminative principal com-
ponents illustrates the difference in mean values between
AMS positive and negative, but shows no clear distinction
between groups (Fig. 4).
Correlation of AMS severity and breath
analysis with an e-nose
Maximum LLS for individuals was used as an indicator of
severity of AMS. Missing diary data for one lowlander at
Namche, although it did not affect AMS diagnosis, did
prevent accurate calculation of total LLS and hence the
subject was excluded from this subset analysis. ANOVA
showed a significant difference between principal compo-
nent 1 and maximum LLS at Namche Bazaar (P = 0.02).
Linear regression analysis indicates a correlation between
both variables (R2 = 0.22, R2 adjusted = 0.20, P = 0.004).
Predictive ability of breath analysis with an
e-nose
The four participants diagnosed with AMS at Namche
Bazaar were excluded. A fifth participant was excluded
because of missing diary entries. Eleven out of the remain-
ing 32 participants were diagnosed with AMS at some time
in their trek from Namche to Everest Base Camp. Following
PCA, pattern-based breath analysis between participants
who remained AMS negative and those that developed
AMS showed a significant difference on principal compo-
nent 1 (P = 0.009). CV-LDA showed correct classification
of 68.8% of cases, ROC-AUC 0.76  0.18, with sensitivity
of 46% and specificity of 81%.
Ability of breath analysis with an e-nose to
distinguish between Sherpas and lowlanders
PCA of Sherpas’ and lowlanders’ breathprints showed sig-
nificant difference on principal component 1 (P = 0.001)
(Fig. 5). CV-LDA showed correct classification of 89.2%
of cases, ROC-AUC 0.936  0.08 (Fig. 6) with sensitivity
of 94.7% and specificity of 83.3%.
Discussion
This study demonstrated the first exhaled breath analyses,
using the Cyranose 320 e-nose at high altitude and it is
the first to have investigated its role in the diagnosis and
prediction of AMS. It is also the first time that an e-nose
has been used to compare breathprints from Sherpas with
lowlanders, further developing the concept that different
hypoxic response phenotypes may be reflected in the pro-
file of exhaled volatiles.
Diagnostic utility of breath analysis with an
e-nose
There is currently no objective method to diagnose and/
or assess AMS. The results of this study provide a strong
Figure 3. ROC Curve demonstrating discrimination between AMS
positive and AMS negative breathprints at Namche Bazaar.
Figure 4. Scatterplot comparing AMS positive (green) with AMS
negative (blue) breathprints at Namche Bazaar.
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signal that breath analysis using an e-nose can distinguish
participants with AMS from those without. Significant
differences between both principal components 1 and 2,
indicate that VOC patterns within these two groups may
be discriminatory. The low number of AMS positive par-
ticipants, however, produced a skewed data set that makes
it difficult to draw definitive conclusions about the diag-
nostic capability of e-noses.
There are indications that breath analysis may have a
role not only in AMS diagnosis but also in assessing
severity. When trekkers were grouped according to their
maximum LLS at the time of sampling, there was a signif-
icant difference between the respective sets of breathprints
and linear regression showed a weak correlation between
LLS and principal component 1.
In light of these results, it is worth considering whether
the AMS negative plots that are grouped close to positive
plots in Figure 4, do in fact represent volatiles generated
from an evolving AMS pathophysiology. A recent study
demonstrated a correlation between exhaled VOCs and
the physiological responses to hypoxic environments (Fig-
ueroa et al. 2015).
Predictive utility of breath analysis with an
e-nose
There was a significant difference between breathprints
from trekkers who remained AMS negative compared to
those who developed AMS later in the expedition; the e-
nose was able to identify those at risk of developing AMS
with reasonable discrimination. There is currently no reli-
able method to risk-stratify people for AMS. The ability
to do so would provide a great advantage to medical
teams, allowing targeted and timely interventions to pre-
vent progression to AMS.
Ability of breath analysis with an e-nose to
distinguish between Sherpas and
lowlanders
There were provocative results for the ability of the e-
nose to distinguish Sherpas from lowlanders. This is an
exciting outcome which supports the use of breath analy-
sis to discriminate between people with different
responses to hypoxia. It also suggests that analysis of
VOCs in exhaled breath may help us to understand better
the physiological mechanisms that result in (mal)adapta-
tion to hypoxia. Alternatively, it is worth considering
whether the differences observed in exhaled VOCs
between Sherpas and lowlanders may be related to behav-
ioral or genetic distinctions that are unrelated to hypoxia.
Study limitations
Our design proved durable to the hostile conditions at
high altitude, supporting the potential use of breath anal-
ysis as an objective assessment tool for AMS. However,
the 27 exclusions detailed in the results merit further dis-
cussion about the reliability of the method under such
conditions. The four failed sample draws may have been
secondary to an incorrect pump speed for low ambient
barometric pressure, since changing to a high-speed set-
ting resolved the issue. This is important for those wish-
ing to use similar apparatus at altitude. The remaining 23
Figure 6. ROC Curve demonstrating discrimination between
breathprints from Sherpas and Lowlanders.
Figure 5. Boxplot comparing breathprints from Sherpas with
Lowlanders.
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exclusions were unexplained anomalies: on four separate
days, in which both Sherpas & lowlanders were tested, the
raw sensor data was grossly abnormal for all trekkers and
across all 32 sensors. The interindividual spread was similar
but the absolute values were substantially different from
samples analyzed on all other testing days. Including these
results for data analysis would make interpretation unreli-
able. One plausible explanation may relate to variations in
the ambient temperature and/or humidity; a problem that
has been identified with e-noses during fieldwork in the
environmental sector (Capelli et al. 2014).
The availability of only one e-nose and the logistical
restrictions of the trek meant it was only possible to sam-
ple breath at one geographical location. The number of
people diagnosed with AMS at the time of breath sam-
pling in Namche Bazaar was low (four out of 37 sub-
jects). This produced a skewed data set which made it
difficult to comment with confidence on the e-nose’s
diagnostic utility. A second reading at Everest Base Camp,
where the proportion of AMS positive subjects was
greater, would have helped draw clearer conclusions.
Likewise, additional breath analysis at sea level would
have helped distinguish if there were differing exhaled
VOC profiles between Sherpas and lowlanders indepen-
dent of the effects of altitude i.e., are the demonstrated
differences in VOCs a result of a constitutive or inducible
physiological process.
The equipment used for breath collection and sampling
was not designed for the purpose and substantial efforts
were made to minimize contamination from components
and ambient air. However, specifically designed equip-
ment which has undergone external validation would help
substantiate results for this and future projects. Further-
more, we would welcome studies to clarify the impact of
environmental variables (i.e., ambient temperature,
humidity, barometric pressure) on e-nose breath analysis
and to support the development of standardized method-
ology for field-based research.
Possible mechanistic explanations
Evidence suggests there is an intimate relationship
between hypoxia and inflammation that is primarily
mediated by hypoxia inducible factor (Eltzschig and Car-
meliet 2011). Nitric oxide production, a hallmark of
inflammation, appears to have an important role in
hypoxic signaling and hypoxia inducible factor induction
(Olson and van der Vliet 2011) and a recent review con-
cluded that increased nitric oxide synthesis is associated
with an improved response to hypoxia (Beall et al. 2012).
Variations in the regulation of this inflammatory response
might, therefore, explain the differing VOC profiles
between AMS-resistant and AMS-susceptible individuals.
Relevance for critical illness
Analysis of exhaled breath VOCs may have potential to
be developed into an objective prognostic and diagnostic
tool for not only AMS, but also other clinical conditions.
If breath analysis can identify the poor responders to
hypobaric hypoxia it may also have utility in identifying
those maladapted to normobaric hypoxia e.g., in critical
illness. Furthermore, if we could identify which volatiles
dominate the differences between individuals then this
may offer a mechanistic insight into the cellular processes
involved and thereby help explain the pathogenesis of
hypoxia (mal)adaptation.
Conclusions
In this study we have demonstrated the feasibility of a
method for exhaled VOC analysis in a remote high altitude
environment using an e-nose (Cyranose 320). Our results
provide proof-of-concept for its use as an objective tool in
the prediction and diagnosis of AMS. The development of
such a tool could have major impacts on altitude medicine
as well as other clinical areas. The ability to differentiate the
breathprints of Sherpas from lowlanders supports the use
of breath analysis to discriminate between different
(patho)physiological responses to hypoxic conditions. It
also suggests that analysis of exhaled breath may provide us
with a route to better mechanistic understanding of
hypoxic (mal)adaptation. Translational research to explore
exhaled breath biomarkers in critical illness could help the
development of improved, phenotype-specific management
strategies for our sickest patients.
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